$599

Companion Medical’s InPen Approved in Peds; BrightInsight Secures $40M Series B Funding

Two diabetes-related items have been observed: Companion Medical announced FDA approval of its InPen for use in all ages and BrightInsight announced a Series B funding round of $40M. Below, FENIX provides thoughts on the expanded indication for InPen and BrightInsight’s funding.

This content is for Read Less members only.
Register
Already a member? Log in here